OTSUKA PHARMACEUTICAL CO., LTD.
π―π΅Japan
- Country
- π―π΅Japan
- Ownership
- Public, Subsidiary
- Established
- 1964-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.otsuka.co.jp
A Long-term Administration Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With Schizophrenia
Phase 3
Active, not recruiting
- Conditions
- Schizophrenia
- Interventions
- First Posted Date
- 2022-04-13
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 190
- Registration Number
- NCT05326347
- Locations
- π―π΅
Hayakawa Clinic, Kure-shi, Japan
Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With Acute Schizophrenia
Phase 3
Recruiting
- Conditions
- Acute Schizophrenia
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-04-13
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 450
- Registration Number
- NCT05325645
- Locations
- π―π΅
Hayakawa Clinic, Kure-shi, Japan
A Clinical Pharmacology Trial of Brexpiprazole Long Acting Injectable (LAI) Administered as a Single Dose in Patients With Schizophrenia
Phase 1
Withdrawn
- Conditions
- Schizophrenia
- First Posted Date
- 2021-11-15
- Last Posted Date
- 2022-04-28
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Registration Number
- NCT05119894
Specified Drug-use Survey on Abilify Prolonged Release Aqueous Suspension for IM Injection (Prevention of Relapse of Mood Episodes in BP)
Completed
- Conditions
- Bipolar Disorder I
- First Posted Date
- 2021-03-23
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 535
- Registration Number
- NCT04812379
- Locations
- π―π΅
Pharmacovigilance Department, Osaka, Japan
Samsca Post-marketing General Drug Use-results Survey in Patients with Hyponatremia in SIADH
Recruiting
- Conditions
- Antidiuretic Hormone, Inappropriate Secretion
- First Posted Date
- 2021-03-10
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 300
- Registration Number
- NCT04790175
- Locations
- π―π΅
Pharmacovigilance Department, Osaka, Japan
A Dose-finding Trial of ETC-1002(Bempedoic Acid) in Patients With Hypercholesterolemia
Phase 2
Completed
- Conditions
- Hypercholesterolemia
- Interventions
- Drug: 180mg of ETC-1002(bempedoic acid)Drug: 120mg of ETC-1002(bempedoic acid)Drug: 60mg of ETC-1002(bempedoic acid)Drug: Placebo
- First Posted Date
- 2021-03-05
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 188
- Registration Number
- NCT04784442
- Locations
- π―π΅
Tokyo-Eki Center-Building Clinic, Chuo-ku,Tokyo, Japan
Safety and Efficacy Study of OPC-415 in Patients With Relapsed and/or Refractory Multiple Myeloma
Phase 1
Recruiting
- Conditions
- Multiple Myeloma (MM)
- Interventions
- Biological: OPC-415
- First Posted Date
- 2020-12-02
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 49
- Registration Number
- NCT04649073
- Locations
- π―π΅
Tokai University Hospital, Isehara-shi, Japan
π―π΅National Hospital Organization Okayama Medical Center, Okayama-shi, Japan
π―π΅Tohoku University Hospital, Sendai-shi, Japan
A Phase 1 Trial of ASTX030 in Patients With Myelodysplastic Syndrome
- First Posted Date
- 2020-10-29
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT04608110
- Locations
- π―π΅
Yamagata University Hospital, Yamagata, Japan
A Phase I/II Study of ASTX660 in Patients With Relapsed or Refractory T-cell Lymphoma
Phase 1
Terminated
- Conditions
- Relapsed or Refractory Peripheral T-cell Lymphoma(PTCL),Cutaneous T-cell Lymphoma(CTCL),Adult T-cell Leukemia/Lymphoma(ATLL)
- Interventions
- First Posted Date
- 2020-04-24
- Last Posted Date
- 2025-01-15
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 61
- Registration Number
- NCT04362007
- Locations
- π―π΅
Yamagata University Hospital, Yamagata, Japan
A Safety Evaluation Trial of TEV-48125 Self-administered in Migraine Patients
Phase 3
Completed
- Conditions
- Migraine
- Interventions
- Drug: Each subject will subcutaneously self-administer TEV 48125 at 225 mg/1.5 mL (150 mg/mL) once monthly for a total of 2 doses.
- First Posted Date
- 2020-04-21
- Last Posted Date
- 2021-10-28
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 71
- Registration Number
- NCT04355117
- Locations
- π―π΅
Sendai Zutsu No-Shinkei Clinic, Sendai, Japan
Β© Copyright 2025. All Rights Reserved by MedPath